Wisconsin · Schedule I · federal-track research active · no 2026 state bill
Wisconsin's psilocybin story is federal-track research, with the state legislature quiet.
Wisconsin runs an active federal-track psilocybin research footprint with no corresponding state-level legislative pathway. UW-Madison's Transdisciplinary Center for Research in Psychoactive Substances (TCRPS), led by Prof. Paul Hutson, runs FDA-authorised trials in psilocybin for major depressive disorder, psilocybin for opioid use disorder, MDMA for PTSD (in MAPS partnerships), and psilocybin safety studies. Usona Institute in Madison received one of three nationwide HHS pediatric/adult drug-development vouchers via April 2026 executive order (Compass Pathways and Transcend Therapeutics received the other two). At the state level, the 107th Legislature adjourned February 20, 2026 with no 2026 psilocybin bills filed. SB 727 (2023) died in the prior session. Schedule I status applies for all general possession.
90-second quick read · research companion
Need the full research version?
This is the 90-second cliff-note read on imicrodosing.net. For the cited deep-dive companion, read the full .org research page before moving into product decisions.
Dual track
How a state runs major research with no state legislation
Wisconsin's policy posture is unusual: significant federal-track research density alongside near-total state-level legislative quiet. The two tracks operate in parallel without intersecting.
Federal-track research at UW-Madison and Usona Institute is moving. The Wisconsin Legislature's state track is quiet — no 2026 bill, no live committee work.
Why this shape
Federal research authority vs state legislative pathways
Psilocybin research operates on federal authority — FDA INDs, DEA Schedule I researcher registrations, federal grants. State legislation governs general access, not research conduct. Wisconsin's research density reflects its federal-track institutional strength (UW-Madison, Usona Institute), independent of state legislative posture.
Prof. Paul Hutson's TCRPS programme is a leading academic node in U.S. psilocybin research. The April 2026 HHS voucher to Usona Institute, alongside Compass Pathways and Transcend Therapeutics, makes Madison one of the three nationwide hubs for HHS-recognised drug development work.
- UW-Madison TCRPS — Prof. Paul Hutson director. FDA-authorised psilocybin and MDMA trials.
- Usona Institute — Madison-based research nonprofit. April 2026 HHS voucher recipient.
- SB 727 (2023) — died in the prior session. No comparable 2026 bill has been filed.
- 107th session adjournment — February 20, 2026. No 2026 psilocybin bill filed before adjournment.
3 cities
Where the policy and the people live
Madison
UW-Madison + Usona Institute
Capital and primary academic-medical centre. TCRPS. Usona HHS voucher recipient.
Madison pageMilwaukee
MCW + Froedtert + Zablocki VA
Largest city, ~567K. Medical College of Wisconsin, Froedtert Hospital, Zablocki VA.
Milwaukee pageGreen Bay
Bellin + Aurora BayCare
Northeastern WI anchor, ~106K. Bellin Health, Aurora BayCare. Oneida Reservation adjacent.
Green Bay pageCommon questions
Wisconsin psilocybin FAQ
Q · 01
Is psilocybin legal in Wisconsin?
No. Psilocybin is Schedule I under Wisconsin's Uniform Controlled Substances Act. General possession is a criminal offence. Federal-track research at UW-Madison TCRPS and Usona Institute operates on federal authority, not general access.
Q · 02
Has Wisconsin filed any psilocybin bill in 2026?
No. The 107th Wisconsin Legislature adjourned February 20, 2026 with no 2026 psilocybin bills having been filed. SB 727 (2023) died in the prior session and has not been refiled.
Q · 03
What is the Usona Institute voucher?
Usona Institute, a Madison-based research nonprofit, received an HHS pediatric/adult drug-development voucher via April 2026 executive order. It is one of three nationwide voucher recipients alongside Compass Pathways and Transcend Therapeutics. The voucher supports federally recognised drug-development work.
Q · 04
What does UW-Madison TCRPS do?
The Transdisciplinary Center for Research in Psychoactive Substances at UW-Madison School of Pharmacy, led by Prof. Paul Hutson, runs FDA-authorised trials including psilocybin for major depressive disorder, psilocybin for opioid use disorder, MDMA-PTSD in MAPS partnerships, and psilocybin safety studies.
Q · 05
Have any Wisconsin cities decriminalised?
No. Madison, Milwaukee, Green Bay, and other Wisconsin municipalities have not adopted independent psilocybin decriminalisation ordinances. Wisconsin carries zero decriminalised cities.
While the federal track advances and state quiet continues
iMicrodosing.com ships lab-verified products within all applicable federal, state, and local laws. For deeper research and clinical context on psilocybin therapy outcomes, imicrodosing.org aggregates the trial literature.